About GLP1Injections Canada

GLP1Injections Canada covers one drug class: the GLP-1 receptor agonists, plus the GIP/GLP-1 dual agonist tirzepatide. We track what each molecule costs in Canada, which licensed Canadian clinics prescribe it, what Health Canada has actually authorised it for, and what the clinical evidence supports.

Why one drug class, and not telehealth generally

Because the details are where this subject goes wrong. People arrive calling the whole category “Ozempic,” when semaglutide, liraglutide and tirzepatide are different molecules on different dosing schedules with different Canadian authorisations. A site covering twelve treatment categories cannot afford the space to get that right. A site covering one can.

The compounding line

Health Canada does not permit compounded semaglutide or tirzepatide. In the United States, compounding pharmacies were permitted to supply these molecules during shortages, and a large share of the GLP-1 content Canadians find online was written on that basis. None of it applies here, and repeating it would send readers toward suppliers operating outside Canadian regulation. We state this on every relevant page rather than leaving it implied.

Why this site is Canada-only

Health Canada authorizes a different set of products than the FDA, so US pricing and US programs do not carry over. Telehealth is regulated provincially rather than federally, so a provider available in Ontario may not serve Quebec. Drug coverage is set provincially too. Regulators, coverage and pricing are all different.

How we rank providers

Rankings weigh four things that genuinely differ between Canadian platforms:

• All-in cost in CAD — the consultation, the medication at a realistic dose, any membership fee and shipping, not the advertised headline price.
• Provincial coverage — which provinces are actually served, and whether Quebec is included.
• Clinical model — whether clinicians are licensed by a provincial College, whether a real assessment is required, and how often follow-up happens.
• Pharmacy model — in-house dispensing versus a third-party transfer, which is where most refill delays originate.

We do not rank on payment. A provider cannot buy a position, and we publish nothing in a category until we have verified availability — which is why several categories on this site are still marked as in editorial testing rather than filled with placeholders.

How we make money

Some links on this site are affiliate links. If you visit a provider through one and become a customer, we may receive compensation at no additional cost to you. That funds the research and keeps the site free. It does not change our rankings, and it does not change the price you pay.

What we are not

We are not a pharmacy, not a telehealth provider, and not a medical practice. We do not prescribe, dispense, or give medical advice. Every clinical decision is made by the licensed clinicians at the provider you choose.